stockrow
Saturday 31 October 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
62.55
1.16
+1.89%
Follow BMY
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
15.59 | 0.00 | 13.60 | 24.25 | 19.79 | 0.00 | 29.05 | 17.16 | 100.51 | 22.27 |
Piotroski F-Score |
8 | 4 | 7 | 6 | 8 | 5 | 3 | 9 | 6 | 6 |
Altman Z-Score |
2.14 | 1.43 | 2.28 | 2.57 | 2.23 | 1.57 | 1.64 | 5.25 | 5.40 | 6.10 |
P/S ratio |
2.28 | 2.37 | 2.43 | 3.33 | 2.99 | 3.29 | 4.19 | 3.76 | 4.85 | 5.11 |
P/FCF ratio |
8.54 | 8.22 | 8.63 | 12.88 | 9.09 | 10.53 | 14.84 | 13.88 | 23.90 | 53.90 |
Altman Z″-Score (non-manufacturers) |
2.01 | 0.57 | 2.71 | 2.26 | 2.41 | 1.30 | 2.37 | 6.36 | 5.66 | 6.36 |
Beneish M-Score |
(2.69) | (3.75) | (2.70) | (2.76) | (2.84) | (3.30) | (1.97) | (2.83) | (3.05) | (2.03) |
P/Operating CF |
55.58 | 25.83 | 25.67 | 46.56 | 34.13 | 41.75 | 50.18 | 23.88 | 90.29 | 68.84 |
Dividend Safety Score |
63 | — | — | — | — | — | — | — | — | — |
P/B ratio |
5.93 | 7.00 | 3.70 | 4.95 | 3.85 | 3.70 | 2.12 | 6.01 | 8.51 | 6.08 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.06 | 26.72 | 12.28 |
EV/Sales |
2.99 | 3.18 | 3.04 | 3.99 | 3.58 | 4.11 | 5.38 | 3.70 | 4.91 | 5.13 |
EV/EBITDA |
10.81 | 125.67 | 7.51 | 10.23 | 8.84 | 49.85 | 20.95 | 12.64 | 17.23 | 15.83 |
EV/Operating CF |
10.18 | 10.10 | 9.86 | 14.08 | 10.25 | 12.45 | 17.15 | 11.81 | 19.34 | 32.60 |
EV/FCF |
11.22 | 11.01 | 10.80 | 15.40 | 10.90 | 13.15 | 19.09 | 13.65 | 24.17 | 54.10 |
Quick Ratio |
0.94 | 0.91 | 1.04 | 0.87 | 1.20 | 1.28 | 1.26 | 1.36 | 1.37 | 1.35 |
Current Ratio |
1.26 | 1.25 | 1.43 | 1.25 | 1.52 | 1.58 | 1.60 | 1.66 | 1.55 | 1.55 |
Net Debt/EBITDA |
2.58 | 31.77 | 1.51 | 1.67 | 1.47 | 9.93 | 4.66 | (0.21) | 0.19 | 0.06 |
Debt/Assets |
50.10% | 53.61% | 41.80% | 40.61% | 40.76% | 42.77% | 35.96% | 21.01% | 23.73% | 19.90% |
Debt/Equity |
2.44 | 3.03 | 1.35 | 1.26 | 1.24 | 1.34 | 0.90 | 0.52 | 0.67 | 0.41 |
Asset Turnover |
0.53 | 0.51 | 0.47 | 0.45 | 0.41 | 0.34 | 0.32 | 0.66 | 0.62 | 0.59 |
Operating CF/Net income |
2.01 | (1.70) | 1.73 | 2.07 | 2.32 | (1.56) | 2.39 | 1.44 | 5.24 | 0.69 |
Capex/Depreciation |
(0.33) | (0.13) | (0.12) | (0.11) | (0.09) | (0.07) | (0.48) | (1.49) | (1.34) | (3.18) |
| 40.43% | (39.01%) | 26.48% | 18.85% | 18.93% | (20.13%) | 10.45% | 37.88% | 7.14% | 28.97% | |
| 7.72% | (9.53%) | 8.36% | 6.14% | 6.14% | (7.26%) | 4.17% | 14.36% | 2.99% | 13.62% | |
ROIC |
11.01% | (9.49%) | 9.26% | 7.88% | 7.96% | (5.90%) | 3.74% | 29.33% | 24.67% | 22.13% |
Return on Tangible Assets |
52.19% | (68.09%) | 49.68% | 54.37% | 40.10% | (53.04%) | 19.88% | 40.70% | 9.78% | 45.28% |
Average Days of Receivables |
86.44 | 81.21 | 88.57 | 78.17 | 73.72 | 72.98 | 107.29 | 92.98 | 110.68 | 104.14 |
Research and Development Expense of Revenue |
20.65% | 23.10% | 20.66% | 20.60% | 21.98% | 23.63% | 23.52% | 28.07% | 31.13% | 25.80% |
Selling, General and Administrative Expense of Revenue |
15.08% | 17.42% | 17.27% | 16.93% | 16.58% | 18.02% | 18.63% | 20.17% | 22.87% | 25.63% |
Intangible Assets out of Total Assets |
0.45 | 0.49 | 0.51 | 0.59 | 0.58 | 0.62 | 0.67 | 0.22 | 0.24 | 0.25 |
Share Based Compensation of Revenue |
1.15% | 1.05% | 1.15% | 0.99% | 1.26% | 1.83% | 1.69% | 0.98% | 0.96% | 1.06% |
Graham Net Nets |
(0.38) | (0.40) | (0.31) | (0.25) | (0.29) | (0.36) | (0.45) | (0.04) | (0.07) | (0.04) |
Graham Number |
26.61 | 0.00 | 35.27 | 31.30 | 33.90 | 0.00 | 38.83 | 24.29 | 9.94 | 24.24 |
Earnings Yield |
6.41% | (7.81%) | 7.35% | 4.12% | 5.05% | (6.45%) | 3.44% | 5.83% | 0.99% | 4.49% |
Free Cash Flow Yield |
11.71% | 12.16% | 11.59% | 7.76% | 11.00% | 9.49% | 6.74% | 7.20% | 4.18% | 1.86% |
Revenue per Share |
23.69 | 23.83 | 21.75 | 21.67 | 20.88 | 18.83 | 15.33 | 13.82 | 12.63 | 11.63 |
Operating CF per Share |
6.96 | 7.49 | 6.70 | 6.13 | 7.30 | 6.22 | 4.82 | 4.33 | 3.21 | 1.83 |
Capex per Share |
(0.64) | (0.62) | (0.58) | (0.52) | (0.44) | (0.33) | (0.49) | (0.58) | (0.64) | (0.73) |
Free Cash Flow per Share |
6.32 | 6.88 | 6.11 | 5.61 | 6.86 | 5.89 | 4.32 | 3.74 | 2.57 | 1.10 |
Cash per Share |
5.25 | 5.36 | 5.94 | 4.34 | 7.64 | 7.01 | 9.03 | 5.36 | 4.14 | 3.80 |
Shareholders Equity per Share |
9.10 | 8.08 | 14.25 | 14.61 | 16.21 | 16.78 | 30.32 | 8.65 | 7.20 | 9.78 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.10 | 8.08 | 14.25 | 14.61 | 16.21 | 16.78 | 30.32 | 8.65 | 7.20 | 9.78 |
Free Cash Flow |
12,845.00 | 13,942.00 | 12,651.00 | 11,948.00 | 15,234.00 | 13,299.00 | 7,374.00 | 6,115.00 | 4,220.00 | 1,843.00 |
Working Capital |
5,973.00 | 6,006.00 | 9,508.00 | 5,383.00 | 11,394.00 | 11,112.00 | 11,050.00 | 7,062.00 | 5,291.00 | 4,863.00 |
Capital Expenditures |
(1,311.00) | (1,248.00) | (1,209.00) | (1,118.00) | (973.00) | (753.00) | (836.00) | (951.00) | (1,055.00) | (1,215.00) |
Net Current Asset Value |
(42,142.00) | (46,435.00) | (33,904.00) | (38,429.00) | (40,046.00) | (50,407.00) | (48,892.00) | (3,143.00) | (6,850.00) | (3,656.00) |
EV/EBIT |
15.45 | 0.00 | 16.19 | 23.85 | 20.51 | 0.00 | 28.30 | 13.99 | 19.88 | 16.86 |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 | 0.05 | 0.06 |
Price to Operating Income |
11.76 | 0.00 | 12.93 | 19.96 | 17.10 | 0.00 | 22.00 | 14.22 | 19.66 | 16.79 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.53 | 1.35 | 1.47 | 1.64 | 1.77 | 1.76 | 0.28 | 0.13 | 0.16 | 0.08 |
Cash ROIC |
17.29% | 18.13% | 15.52% | 14.99% | 15.62% | 12.74% | 6.48% | 20.22% | 15.85% | 6.27% |
Accounts Receivable Turnover |
4.35 | 4.46 | 4.33 | 4.79 | 5.19 | 5.25 | 3.89 | 3.75 | 3.51 | 3.95 |
Accounts Payable Turnover |
3.88 | 4.07 | 3.40 | 3.39 | 3.51 | 4.56 | 3.73 | 3.12 | 3.07 | 3.08 |
Inventory Turnover |
5.31 | 5.35 | 4.28 | 4.57 | 4.77 | 3.70 | 2.94 | 5.48 | 5.00 | 4.04 |
Average Days of Payables |
93.63 | 94.12 | 111.24 | 109.46 | 108.29 | 84.11 | 110.48 | 106.79 | 136.44 | 122.23 |
Days of Inventory on Hand |
70.45 | 66.82 | 90.87 | 84.22 | 76.93 | 64.30 | 193.98 | 67.45 | 70.77 | 91.16 |
Average Receivables |
11,080.50 | 10,834.00 | 10,403.50 | 9,627.50 | 8,935.00 | 8,093.00 | 6,716.00 | 6,023.50 | 5,921.50 | 4,921.00 |
Average Payables |
3,588.50 | 3,430.50 | 3,149.50 | 2,994.50 | 2,831.00 | 2,579.00 | 2,168.50 | 2,070.00 | 1,956.00 | 1,614.50 |
Average Inventory |
2,623.50 | 2,609.50 | 2,500.50 | 2,217.00 | 2,084.50 | 3,183.50 | 2,744.00 | 1,180.50 | 1,203.50 | 1,231.00 |
Average Assets |
91,320.50 | 93,881.00 | 95,989.50 | 103,067.00 | 113,897.50 | 124,212.50 | 82,465.00 | 34,268.50 | 33,629.00 | 32,727.50 |
Average Common Equity |
17,447.00 | 22,936.50 | 30,301.50 | 33,562.00 | 36,944.00 | 44,790.00 | 32,912.50 | 12,987.00 | 14,097.00 | 15,385.50 |
Columns are period end dates